- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
FDA Accepts Ranibizumab BLA From Samsung Bioepis and Biogen
The FDA's acceptance of the biologics license application (BLA) moves the companies one step closer to entering the US ophthalmology treatment sphere with a biosimilar.
Samsung Bioepis and Biogen said the FDA has accepted for review their biologics license application for a ranibizumab biosimilar candidate (SB11), referencing Lucentis, a Genentech product. The drug is an anti–vascular endothelial growth factor treatment for retinal vascular disorders, a leading cause of blindness.
SB11 was developed by Samsung Bioepis and Biogen is the commercialization partner, according to an agreement the companies signed in November 2019.
“The FDA filing acceptance for SB11 brings us a step closer to our goal of being able to offer affordable treatment options for people with retinal vascular disorders,” said Hee Kyung Kim, senior vice president and Clinical Sciences Division and Regulatory Affairs team leader for Samsung Bioepis.
The European Medicines Agency accepted the marketing application for SB11 in October 2020. The corporate partners already market several biosimilars on the European market, including an etanercept (Benepali), adalimumab (Imraldi), and infliximab (Flixabi).
Samsung Bioepis and Biogen also plan to bring an aflibercept biosimilar (SB15) to market in the United States, Canada, Europe, Japan, and Australia. In the United States, aflibercept (Eylea) is indicated for the treatment of macular degeneration, macular edema, and diabetic retinopathy.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
